Premium
Optimizing skeletal‐related events prevention in patients with advanced prostate cancer
Author(s) -
Leung Angus KwongChuen
Publication year - 2020
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.13315
Subject(s) - zoledronic acid , denosumab , medicine , prostate cancer , spinal cord compression , oncology , bone metastasis , bone density conservation agents , diphosphonates , cancer , osteoporosis , bone mineral , bone resorption , spinal cord , psychiatry
In patients with metastatic castration‐resistant prostate cancer (mCRPC), bone is a dominant site of metastasis. Bone metastases often lead to skeletal‐related events (SREs), which include pain, spinal cord compression and fractures. The treatment of bone metastases in men with mCRPC aims to improve SRE‐free survival, quality of life and clinical outcomes. Effective treatment options include antiresorptive bone‐targeted agents such as zoledronic acid and denosumab, and radium‐223, a bone‐targeting radiopharmaceutical. Although overseas and local guidelines have widely recommended using either zoledronic acid or denosumab for the prevention of SREs in men with mCRPC and associated bone metastases, current evidence suggests that denosumab is superior to zoledronic acid in terms of longer SRE‐free time and fewer total SREs observed in patients.